z-logo
Premium
Treatment response in the neck: p16+ versus p16− oropharyngeal cancer
Author(s) -
Mak Daisy,
Hicks Rodney J,
Rischin Danny,
Solomon Ben,
Peters Lester,
Bressel Mathias,
Young Richard J,
Corry June
Publication year - 2013
Publication title -
journal of medical imaging and radiation oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 43
eISSN - 1754-9485
pISSN - 1754-9477
DOI - 10.1111/1754-9485.12024
Subject(s) - medicine , nodal , positron emission tomography , chemoradiotherapy , nuclear medicine , stage (stratigraphy) , head and neck cancer , cancer , standardized uptake value , radiology , oncology , paleontology , biology
Abstract Introduction To compare nodal response rates following chemoradiotherapy in patients with p16+ and p16− oropharyngeal squamous cell carcinoma ( OPSCC ). Methods Patients with node‐positive OPSCC treated at P eter M ac C allum C ancer C entre on the published phase I–III tirapazamine trials were identified. All patients had conventional assessment (clinical examination ( CA ), CT and/or MRI ) and positron emission tomography ( PET ) at both baseline and 2–4 months post‐treatment. Results There were 30 p16+ and 18 p16− patients, the former group having significantly higher stage nodal disease ( P  = 0.016). The mean overall reduction in nodal size at post‐treatment assessment was similar in p16+ and p16− patients (78% vs. 75%), and no statistically significant difference in nodal complete response ( CR ) rates was detected by either CA (50% vs. 39%, P  = 0.35) or PET / PET ‐ CT (93% vs. 83%, P  = 0.19). PET was significantly more accurate in determining the true nodal CR rate in both groups, with a negative predictive value of 96%. Conclusion Nodal response rates following chemoradiotherapy appear to be similar in p16+ and p16− patients when assessed by either CA or PET / PET ‐ CT . However, higher nodal CR was seen in PET / PET ‐ CT compared with CA in both groups. Metabolic imaging is more accurate than CA in assessing nodal response post‐treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here